| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ErbB3 |
| Uniprot No | P21860 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-643aa |
| 氨基酸序列 | SEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTG HNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFV MLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRD RDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCF GPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLT FQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKM CEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLN GDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIG GRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLN WTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLS CRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSG SDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQ GCKGPELQDCLGQTLVLIGKTHLT |
| 预测分子量 | 95 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ErbB3重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*Mechanisms of ErbB3-mediated resistance in cancer therapeutics*
**作者**：Sergina, N. V., et al.
**摘要**：该研究通过重组ErbB3蛋白实验，揭示了ErbB3在EGFR抑制剂耐药性中的关键作用，证明其可通过激活PI3K/AKT信号通路绕过靶向治疗抑制，为联合疗法提供理论依据。
---
2. **文献名称**：*Structural basis for ligand-induced activation of ErbB3 signaling*
**作者**：Jura, N., et al.
**摘要**：利用重组ErbB3胞外域蛋白进行X射线晶体学分析，解析了ErbB3与配体heregulin结合的构象变化，阐明其激活同源或异源二聚化(如与ErbB2)的分子机制。
---
3. **文献名称**：*Recombinant expression and functional characterization of ErbB3 in breast cancer models*
**作者**：Zhang, Y., et al.
**摘要**：通过哺乳动物细胞系统重组表达ErbB3蛋白，验证其在乳腺癌细胞中的促增殖功能，并筛选出靶向ErbB3的单克隆抗体，抑制配体依赖的肿瘤生长。
---
**注**：以上文献为示例性质，具体发表年份及期刊需根据实际检索结果调整。建议通过PubMed或Web of Science以“ErbB3 recombinant protein”为关键词进一步筛选最新研究。
ErbB3 (HER3), a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family, plays a critical role in cellular signaling pathways regulating cell proliferation, differentiation, and survival. Unlike other EGFR family members (EGFR, HER2. HER4), ErbB3 lacks intrinsic kinase activity due to mutations in its kinase domain. To activate downstream signaling, it must heterodimerize with other ligand-activated receptors, particularly HER2. making this partnership a key driver in oncogenic signaling, especially in cancers resistant to EGFR/HER2-targeted therapies.
Recombinant ErbB3 proteins are engineered to study its structure, function, and interactions. These proteins are typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which is essential for ligand binding and receptor activation. The recombinant form often includes the extracellular domain (ECD), which binds ligands like neuregulins (NRG1/2), or full-length constructs for cell-based assays. Purification methods like affinity chromatography (e.g., His-tag or Fc-fusion systems) yield high-purity proteins for research applications.
In cancer biology, recombinant ErbB3 is used to investigate mechanisms of drug resistance, particularly in HER2-positive breast and lung cancers. It also serves as a tool to screen therapeutic antibodies or small-molecule inhibitors targeting ErbB3-driven pathways, such as PI3K/Akt, which are crucial for tumor survival. Beyond oncology, ErbB3’s role in neural development and tissue repair has spurred interest in regenerative medicine. Despite its therapeutic potential, challenges remain in targeting ErbB3 due to its kinase-dead nature and complex dimerization dynamics, underscoring the need for advanced recombinant protein tools to unravel its pathophysiological nuances.
×
